Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional

Gastrointestinal (Colorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).

Zhen Zhang

3510

A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Primary analysis of Japan Clinical Oncology Group study JCOG1006.

Yasumasa Takii

3515

Aspirin as adjuvant treatment for colorectal cancer: Rationale and progress of the Add-Aspirin trial.

Ruth E Langley

TPS3624

Clinical downstaging and quality of life after neoadjuvant chemotherapy in patients with locally advanced rectal cancer: Interim analysis from a phase II clinical trial.

Ahmed Abdalla

e15178

Current treatment strategies and patterns of recurrence in locally advanced colon cancer.

Caroline Huynh

e15171

Effect of neoadjuvant treatment on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma: A post-hoc analysis from 3 prospective studies.

Jianwei Zhang

3608

Efficacy of aspirin for stage III colorectal cancer: A randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial).

Atsuo Takashima

TPS3623

Exosomal microRNA-199b-5p as a potential circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer.

Dong Won Baek

e15161

Factors of local immunity in patients with rectal cancer after prolonged radiotherapy.

Oleg Ivanovich Kit

e15164

FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

Matthew T. Seymour

3504

Incidence and severity of postoperative complications following neoadjuvant therapy and full-thickness local excision for moderately advanced rectal cancer.

Ahmed Abdalla

e15167

Liver findings and risk of recurrence in locally-advanced rectal cancer (LARC): An Italian retrospective cohort study.

Angela Damato

e15175

LONG TERM opioid use in RURAL NON-metastatic colon cancer patients.

Emilio Paul Araujo-Mino

e15174

Long-term outcomes after high-dose chemoradiotherapy for non-surgical management of distal rectal cancer.

Edina Dizdarevic

3611

Neoadjuvant treatment of adenocarcinoma of the rectum: Historical analysis and correlation between pathological regression rate and the outcomes.

Jeziel Basso

e15177

Nomogram incorporated the number of adjuvant chemotherapy cycles for predicting the prognosis in stage II-III rectal cancer patients without neoadjuvant therapy.

Weiwei Chen

e15163

Patient reported outcome measures (PROMs) in patients (pts) with locally advanced rectal cancer (LARC) managed with a watch and wait (W&W) approach after a clinical complete response to chemoradiotherapy (CRT).

Sina Vatandoust

e15173

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

Michael Michael

TPS3622

Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer: Preliminary analysis of the PePiTA study.

Alain Hendlisz

3610

Prognostic factors for severe diarrhea in patients with locally advanced rectal carcinoma treated with neoadjuvant chemoradiation with capecitabine: A single-center cohort study.

Wesley Hartman

e15176

Prognostic impact of SOX9 in stage II colon cancer: Results from a large nationwide cohort.

Torben Hansen

e15165

Prognostic nutritional index and colorectal cancer deaths: A retrospective cohort study in Chinese patients with locally advanced colorectal cancer.

Wenling Wang

e15160

Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).

Jean Francois Delattre

3519

Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson

3501

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).

Frank A. Sinicrope

e15169

Rectal admission of chemotherapeutic drugs in neoadjuvant treatment schemes of locally advanced rectal cancer.

Luiza Korytova

e15168

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

Qian Shi

3502

Reirradiation and/or surgery for locoregionally recurrent rectal cancer: A systemic review and meta-analyses.

Chai Hong Rim

e15159

Risk factors predicting colorectal cancer recurrence in a Latin American population.

Jorge Leon

e15180

Stage of disease and initial surgical intervention in colon cancer patients: An exploratory analysis of the SEER database.

Rachel Gray Denneny

e15170

Stage-based variation in the impact of colon cancer surveillance.

Lucy Gately

3609

The genomic landscape and its prognostic significance for stage III colorectal cancer in Japan: An ancillary study of JCOG0910 trial—JCOG1506A1.

Dai Shida

3607

The prognostic significance of magnetic resonance imaging (MRI) following neoadjuvant concurrent chemoradiation (NCCR) in patients with locally advanced rectal adenocarcinoma (LARA).

Yazan Fahmawi

e15166

Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

Ioannis Sougklakos

3500

Utilization of surgery and its impact on survival in elderly patients with localized colon cancer in the United States.

Lubina Arjyal

e15179

Validation of neoadjuvant rectal cancer(NAR) score as a surrogate endpoint for disease free survival in Chinese FOWARC study.

Yanhong Deng

e15162

Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.

Takayuki Yoshino

3606